Voriconazole-induced retinoid-like photosensitivity in children

Pediatric Dermatology

Volumn 21, Issue 6, 2004, Pages 675-678

  Rubenstein, Melissa ^a   Levy, Moise L ^a   Metry, Denise ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MAGNESIUM OXIDE; MONTELUKAST; SALMETEROL; SULFAMETHIZOLE; TRIMETHOPRIM; VORICONAZOLE;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; BULLOUS SKIN DISEASE; CASE REPORT; CHRONIC GRANULOMATOUS DISEASE; CLINICAL EXAMINATION; DESQUAMATION; ERYTHEMA; FAMILY HISTORY; FOLLOW UP; HUMAN; MALE; PHOTOSENSITIVITY; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; MALE; PHOTOSENSITIVITY DISORDERS; PROGNOSIS; PYRIMIDINES; RETINOIDS; TRIAZOLES;

EID: 10644234678     PISSN: 07368046     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0736-8046.2004.21614.x     Document Type: Article

References (26)

1. Winkelstein JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine 2000;79:155-169.
2. Abassi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999;29:1210-1219.
3. Luke R, Boyle J. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998;3:780-785.
4. Kauffman C, Carver P. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997;53:539-549.
5. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-248.
6. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother 2000;34:1032-1043.
7. Sheehan DJ, Hitchcock CA, Sibleyo CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1998;12:40-79.
8. Ghannoum MA, Hossain MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Invest Drugs 2000;9:1797-1813.
9. Schlamm HT, Corey L, Brown W, Perfect J. Voriconazole for salvage treatment of invasive aspergillosis. Presented at the 38th Infectious Diseases Society of America Meeting, New Orleans, 2000.
10. Perfect J, Gonzalez-Ruiz A, Lutsar I, et al. Voriconazole for the treatment of resistant and rare fungal pathogens. Presented at the 38th Infectious Diseases Society of America Meeting, New Orleans, 2000.
11. Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003;37:420-432.
12. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
13. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, Voriconazole (UK-109,496) blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-2496.
14. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-637.
15. Vfend® (voriconazole) product information. New York: Pfizer-Roerig Pharmaceuticals, 2002.
16. Orfanos CE, Ehlert R, Gollnick H. The retinoids: a review of their clinical pharmacology and therapeutic use. Drugs 1987;34:459-503.
17. Duell EA, Astrom A, Griffiths CEM, et al. Human skin levels of retinoid acid and cytochrome P-450 derived 4-hydroxyretinoic acid after topical application and retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. J Clin Invest 1992;90:1269-1274.
18. Mohammed KN. Severe photodermatitis during ketoconazole therapy. Clin Exp Dermatol 1988;13:54-55.
19. Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:1-36.
20. Alvarez JG, Castano-Suarez E, Comejo-Navarro P, et al. Photosensitivity induced by oral itraconazole. J Eur Acad Dermatol Venereol 2000;14:501-503.
21. Denning DW, Griffiths CEM. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001;26:648-653.
22. Swift AC, Denning DW. Skull base osteitis following fungal sinusitis. J Laryngol Otol 1998;112:92-97.
23. Van Wauwe JP, Coene MC, Goosens J, et al. Effects of cytochrome P450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990;252:365-369.
24. Harrier J, Enderlin A, Seger RA, et al. Discoid lupus erythematosus-like lesions in carriers of X-linked chronic granulomatous disease. Br J Dermatol 1992;127:446-447.
25. Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. Recent advances in chronic granulomatous disease. Ann Intern Med 1983;99:657-674.
26. Strate M, Brandrup F, Wang P. Discoid lupus erythematosus-like skin lesions in a patient with autosomal recessive chronic granulomatous disease. Clin Genet 1986;30:184-190.